Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.

Core Viewpoint - Appili Therapeutics Inc. has formally terminated its arrangement agreement with Aditxt Inc. and is entitled to a termination fee of USD 1,250,000, with USD 1,000,000 remaining payable after adjustments [1][2]. Group 1: Termination of Arrangement Agreement - The termination of the arrangement agreement with Aditxt is effective as of May 30, 2025 [1]. - Appili is entitled to a termination fee of USD 1,250,000, which has been reduced by previous payments made by Aditxt [2]. - The remaining amount of USD 1,000,000 is still payable to Appili [2]. Group 2: Financial Arrangements - In connection with the termination, Appili has secured 3-month extensions on amounts due under its secured loan agreement with Long Zone Holdings Inc. and unsecured promissory notes with Bloom Burton & Co. Inc. [3]. - All amounts owed under these loans, including accrued interest, will be due on August 31, 2025 [3]. Group 3: Company Overview - Appili Therapeutics is focused on developing therapies for infectious diseases and medical countermeasures [4]. - The company aims to address urgent infections with unmet needs and is advancing a diverse range of anti-infectives, including an FDA-approved treatment for antimicrobial-resistant infections [4]. - Appili is led by a proven management team and is positioned at the forefront of the global fight against infections [4].